Method of treating hematologic tumors and cancers

Details Method of treating hematologic tumors and cancers Method of treating hematologic tumors and cancers

2006-07-04

2006-07-04

Page, Thurman K. (Department: 1615)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S400000, C514S772400, C514S773000, C514S776000, C514S781000

Reexamination Certificate

active

07070797

ABSTRACT:
Multiple myeloma and other hematologic tumors and/or malignancies can be treated by administration of a G1 and/or S phase drug, which is preferably β-lapachone, or a derivative or analog thereof, combined with a G2/M phase drug such as a taxane derivative, which is advantageously paclitaxel. This combination of the G1 and/or S phase drug with the G2/M phase drug results in an unexpectedly greater than additive (i.e., synergistic) apoptosis in multiple myeloma cells. The invention includes methods of treating multiple myeloma by administering the combination of the G1 and/or S phase drug and the G2/M phase drug, pharmaceutical compositions comprising the combination of drugs used in these methods, as well as pharmaceutical kits.

REFERENCES:
patent: 5424073 (1995-06-01), Rahman et al.
patent: 5440056 (1995-08-01), Klein et al.
patent: 5760072 (1998-06-01), De Bont et al.
patent: 5763625 (1998-06-01), Boothman et al.
patent: 5773461 (1998-06-01), Wittman et al.
patent: 5807888 (1998-09-01), Pandey et al.
patent: 5824700 (1998-10-01), Frydman et al.
patent: 5969163 (1999-10-01), Frydman et al.
patent: 6245807 (2001-06-01), Pardee et al.
patent: WO 94/04145 (1994-03-01), None
patent: WO 96/33988 (1996-10-01), None
patent: WO 97/08162 (1997-03-01), None
patent: WO 97/31936 (1997-09-01), None
patent: WO0731936 (1997-09-01), None
patent: WO 00/61142 (2000-10-01), None
patent: WO0061142 (2000-10-01), None
Li et al, Potent Inhibition of tumor survival in vivo by Beta lapachone plus taxol: Combining drugs imposes different artificial checkpoints, Nov. 9, 1999, PNAS, vol. 96, No. 23, pp. 13369-13374.
Li et al, Potent Induction of Apoptosis by Beta-Lapachone in Human Multiple Myeloma Cell Lines and patient Cells, Dec. 6, 2000, Molecular medicine, vol. 6, No. 12, pp. 1008-1015.
Li et al, Potent Inhibition of tumor survival in vivo by Beta lapachone plus taxol: Combining drugs imposes different artificial checkpoints, Nov. 9, 1999, PNAS, vol. 96, No. 23, pp. 13369-13374.
Li, et al. (1995).Cancer Res. 55: 3712-3715.
Li, et al. (1999).Proc. Natl. Acad. Sci. USA 96(23): 13369-74.
Li (1999).Mol. Med. 5: 232-239.
Schaffner-Sabba, et al. (1984).J. Med. Chem. 27: 990-4.
Li, et al. (1993).J. Biol. Chem. 268(30): 22463-8.
Goncalves, et al. (1998).Mol. and Biochem Parasitology 1: 167-76. (1998).
Longo (1998).Harrison's Principles of Internal Medicine14thedition: 713. (McGraw-Hill, New York).
Case, et al. (1977).Am. J. Med. 63: 897-903.
Otsuki, et al. (2000).Cancer Res. 60: 1.
Hooker (1936).J. Am. Chem. Soc. 58: 1181-1190.
Goncalves de Lima, et al. (1962).Rev. Inst. Antibiot. Univ. Recife. 4: 3-17.
Li, et al. (1993).Proc. Natl. Acad. Sci. USA 90: 1839-1842.
Schuerch and Wehrli (1978).Eur. J. Biochem. 84: 197-205.
Boorstein, et al. (1984).Biochem. Biophys. Res. Commun. 118(3): 828-834.
Boothman, et al. (1989).Cancer Res. 49: 605-612.
Tu, et al. (1996).Blood 88(5): 1805-1812.
Bloem and Lockhorst (1999).Pathol. Bio.(Paris)47: 216-220.
Elledge (1996).Science 274: 1664-1672.
Hartwell and Kastan (1994).Science 266: 1821-1828.
Nurse (1997).Cell 91: 865-867.
Tang, et al. (2000).Science 287: 640-642.
Kingston, et al. (1986). “New Trends in Natural Products Chemistry”Studies in Organic Chem. 26: 219-235.
Mosmann (1983).J. Immunol. Methods 65: 55-63.
Treon, et al. (1998).Blood 92: 1749-1757.
Portela, et al. (1996).Biochem Pharm 51: 275-283.
Maruyama, et al. (1977).Chem Lett847-850.
Sun, et al. (1998).Tetrahedron Lett 39: 8221-8224.
Gupta, et al. (1978).Indian Journal of Chemistry 16B: 35-37.
Gupta, et al. (1977).Curr Sci 46: 337.
DiChenna, et al. (2001).J Med Chem 44: 2486-2489.
Reme, et al. (2001).Br J Haematol 114: 406.
Suzuki, et al. (1992).Eur J Immunol 22: 1989.
Gado, et al. (2001).Haematologica 86: 227.
Dallas, et al. (1999)Blood 93: 1697.
Manning, et al. (1995).Immunol Cell Biol. 73: 326.
Takura, et al. (1996).Cancer Res 26: 2564.
Potter, et al. (1985).J Exp Med 161: 996.
Yaccoby, et al. (1998).Blood 92: 2908.
Urashima, et al. (1997).Blood 90: 754.
Frank, et al. (1976).Am J Pathol 83: 367.
Donaubauer, et al. (1998).Regul Toxicol Pharmacol 27: 189.
Uekama and Otagirl. (1987).Crit Rev Ther Drug Carrier Syst 3: 1.
Medline Online Database XP002241805 (NLM7641180) (1995) (See, Planchon et al. (1995)Cancer Res 55(17): 3706-3711).
Zhang et al. (1998).Leukemia 12(9): 1383-1391.
Gazitt et al. (1998).International Journal of Oncology 13(4): 839-848.
Li et al. (2000).Mol. Med. 6(12): 1008-1015.

Affiliated with

Also associated with

Rating

Method of treating hematologic tumors and cancers does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method of treating hematologic tumors and cancers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating hematologic tumors and cancers will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3533888